Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99


Synergistic role of Sprouty2 inactivation and c-Met up-regulation in mouse and human hepatocarcinogenesis.

Lee SA, Ladu S, Evert M, Dombrowski F, De Murtas V, Chen X, Calvisi DF.

Hepatology. 2010 Aug;52(2):506-17. doi: 10.1002/hep.23681.


Inactivation of Spry2 accelerates AKT-driven hepatocarcinogenesis via activation of MAPK and PKM2 pathways.

Wang C, Delogu S, Ho C, Lee SA, Gui B, Jiang L, Ladu S, Cigliano A, Dombrowski F, Evert M, Calvisi DF, Chen X.

J Hepatol. 2012 Sep;57(3):577-83. doi: 10.1016/j.jhep.2012.04.026. Epub 2012 May 19.


Integration of genomic analysis and in vivo transfection to identify sprouty 2 as a candidate tumor suppressor in liver cancer.

Lee SA, Ho C, Roy R, Kosinski C, Patil MA, Tward AD, Fridlyand J, Chen X.

Hepatology. 2008 Apr;47(4):1200-10. doi: 10.1002/hep.22169.


Pleiotropic effects of methionine adenosyltransferases deregulation as determinants of liver cancer progression and prognosis.

Frau M, Feo F, Pascale RM.

J Hepatol. 2013 Oct;59(4):830-41. doi: 10.1016/j.jhep.2013.04.031. Epub 2013 May 7. Review.


Sprouty 2, an inhibitor of mitogen-activated protein kinase signaling, is down-regulated in hepatocellular carcinoma.

Fong CW, Chua MS, McKie AB, Ling SH, Mason V, Li R, Yusoff P, Lo TL, Leung HY, So SK, Guy GR.

Cancer Res. 2006 Feb 15;66(4):2048-58.


Expression of sprouty2 inhibits B-cell proliferation and is epigenetically silenced in mouse and human B-cell lymphomas.

Frank MJ, Dawson DW, Bensinger SJ, Hong JS, Knosp WM, Xu L, Balatoni CE, Allen EL, Shen RR, Bar-Sagi D, Martin GR, Teitell MA.

Blood. 2009 Mar 12;113(11):2478-87. doi: 10.1182/blood-2008-05-156943. Epub 2009 Jan 15.


AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of rapamycin complex 1), FOXM1 (forkhead box M1)/SKP2, and c-Myc pathways.

Ho C, Wang C, Mattu S, Destefanis G, Ladu S, Delogu S, Armbruster J, Fan L, Lee SA, Jiang L, Dombrowski F, Evert M, Chen X, Calvisi DF.

Hepatology. 2012 Mar;55(3):833-45. doi: 10.1002/hep.24736. Epub 2011 Dec 19.


Down-regulation of Sprouty2 in non-small cell lung cancer contributes to tumor malignancy via extracellular signal-regulated kinase pathway-dependent and -independent mechanisms.

Sutterlüty H, Mayer CE, Setinek U, Attems J, Ovtcharov S, Mikula M, Mikulits W, Micksche M, Berger W.

Mol Cancer Res. 2007 May;5(5):509-20.


Deregulated expression of sprouty2 and microRNA-21 in human colon cancer: Correlation with the clinical stage of the disease.

Feng YH, Wu CL, Tsao CJ, Chang JG, Lu PJ, Yeh KT, Uen YH, Lee JC, Shiau AL.

Cancer Biol Ther. 2011 Jan 1;11(1):111-21. Epub 2011 Jan 1.


The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications.

Delire B, Stärkel P.

Eur J Clin Invest. 2015 Jun;45(6):609-23. doi: 10.1111/eci.12441. Epub 2015 May 11. Review.


MUC15 inhibits dimerization of EGFR and PI3K-AKT signaling and is associated with aggressive hepatocellular carcinomas in patients.

Wang RY, Chen L, Chen HY, Hu L, Li L, Sun HY, Jiang F, Zhao J, Liu GM, Tang J, Chen CY, Yang YC, Chang YX, Liu H, Zhang J, Yang Y, Huang G, Shen F, Wu MC, Zhou WP, Wang HY.

Gastroenterology. 2013 Dec;145(6):1436-48.e1-12. doi: 10.1053/j.gastro.2013.08.009. Epub 2013 Aug 9.


Casein kinase 1 regulates Sprouty2 in FGF-ERK signaling.

Yim DG, Ghosh S, Guy GR, Virshup DM.

Oncogene. 2015 Jan 22;34(4):474-84. doi: 10.1038/onc.2013.564. Epub 2014 Jan 27.


Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice.

Hu J, Che L, Li L, Pilo MG, Cigliano A, Ribback S, Li X, Latte G, Mela M, Evert M, Dombrowski F, Zheng G, Chen X, Calvisi DF.

Sci Rep. 2016 Feb 9;6:20484. doi: 10.1038/srep20484.


Evidence that sprouty 2 is necessary for sarcoma formation by H-Ras oncogene-transformed human fibroblasts.

Lito P, Mets BD, Kleff S, O'Reilly S, Maher VM, McCormick JJ.

J Biol Chem. 2008 Jan 25;283(4):2002-9. Epub 2007 Nov 28.


Sprouty2 suppresses the inflammatory responses in rheumatoid arthritis fibroblast-like synoviocytes through regulating the Raf/ERK and PTEN/AKT signals.

Zhang W, Du Z, Zhu J, Yu J, Xu Y.

Mol Immunol. 2015 Oct;67(2 Pt B):532-9. doi: 10.1016/j.molimm.2015.07.033. Epub 2015 Aug 8.


Sprouty2, PTEN, and PP2A interact to regulate prostate cancer progression.

Patel R, Gao M, Ahmad I, Fleming J, Singh LB, Rai TS, McKie AB, Seywright M, Barnetson RJ, Edwards J, Sansom OJ, Leung HY.

J Clin Invest. 2013 Mar;123(3):1157-75. doi: 10.1172/JCI63672. Epub 2013 Feb 22.


Regulation of Sprouty2 stability by mammalian Seven-in-Absentia homolog 2.

Nadeau RJ, Toher JL, Yang X, Kovalenko D, Friesel R.

J Cell Biochem. 2007 Jan 1;100(1):151-60.


Down-regulation of Sprouty2 via p38 MAPK plays a key role in the induction of cellular apoptosis by tumor necrosis factor-alpha.

Ding W, Warburton D.

Biochem Biophys Res Commun. 2008 Oct 24;375(3):460-4. doi: 10.1016/j.bbrc.2008.08.037. Epub 2008 Aug 17.


Sprouty2 downregulation plays a pivotal role in mediating crosstalk between TGF-beta1 signaling and EGF as well as FGF receptor tyrosine kinase-ERK pathways in mesenchymal cells.

Ding W, Shi W, Bellusci S, Groffen J, Heisterkamp N, Minoo P, Warburton D.

J Cell Physiol. 2007 Sep;212(3):796-806.


FAK is required for c-Met/β-catenin-driven hepatocarcinogenesis.

Shang N, Arteaga M, Zaidi A, Stauffer J, Cotler SJ, Zeleznik-Le NJ, Zhang J, Qiu W.

Hepatology. 2015 Jan;61(1):214-26. doi: 10.1002/hep.27402. Epub 2014 Nov 25.

Supplemental Content

Support Center